Record-Breaking Price Movement
On 29 June 2026, Venus Remedies Ltd's stock price surged to Rs. 2,037.9, setting a fresh 52-week and all-time high. This milestone was accompanied by a notable 5.00% gain on the day, significantly outperforming the Sensex, which declined by 0.20%. The stock opened with a gap-up of 2.63% and maintained strong intraday momentum, touching an intraday high that represented a 4.73% increase from the previous close. The trading session was marked by high volatility, with an intraday volatility measure of 485.92%, reflecting active investor participation and dynamic price action.
Venus Remedies has demonstrated consistent strength, trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bullish trend. The stock has recorded gains for four consecutive days, delivering a cumulative return of 19.69% during this period, further highlighting its upward trajectory.
Long-Term Outperformance Against Benchmarks
The stock's performance over various time horizons has been exceptional when compared to broader market indices. Over the past year, Venus Remedies has generated a remarkable return of 345.13%, vastly outpacing the Sensex's decline of 8.46%. Year-to-date, the stock has appreciated by 166.38%, while the Sensex fell by 9.71%. Even over longer periods, the company has delivered substantial gains: a 3-year return of 678.19% versus the Sensex's 20.39%, and a 10-year return of 2,391.65% compared to the Sensex's 187.76%. These figures underscore the company's ability to consistently outperform the market and its sector peers.
Financial Strength and Growth Metrics
Venus Remedies Ltd's financial results have been notably positive, reflecting strong operational execution. The company reported a net profit growth of 126.19% in the latest quarter, with a quarterly PAT of Rs. 47.50 crores. Net sales for the quarter stood at Rs. 259.40 crores, marking a 33.05% increase. Operating profit has expanded at an annual rate of 45.72%, indicating healthy margin improvement and efficient cost management.
The company’s return on capital employed (ROCE) reached a high of 19.85% in the half-year period, signalling effective utilisation of capital resources. Additionally, Venus Remedies remains net-debt free, bolstering its financial stability and flexibility. The company has declared positive results for six consecutive quarters, reinforcing a pattern of consistent profitability and growth.
Valuation and Market Positioning
Venus Remedies currently trades at a price-to-earnings (P/E) ratio of 25x, with a price-to-book value (P/BV) of 3.92x. Its enterprise value to EBITDA stands at 17.04x, while the PEG ratio is notably low at 0.15x, reflecting the company’s strong earnings growth relative to its valuation. The stock’s premium valuation is supported by its robust financial performance and market leadership within the Pharmaceuticals & Biotechnology sector.
Institutional investors have increased their stake by 0.72% over the previous quarter, collectively holding 4% of the company’s shares. This growing institutional participation reflects confidence in the company’s fundamentals and long-term prospects.
Technical Indicators and Market Sentiment
The technical outlook for Venus Remedies remains bullish, with multiple indicators confirming the positive trend. The Moving Average Convergence Divergence (MACD), Bollinger Bands, KST, Dow Theory, and On-Balance Volume (OBV) all signal strength on both weekly and monthly charts. The stock’s immediate support level is at Rs. 423.70, the 52-week low, while the recent all-time high of Rs. 2,037.95 represents a strong resistance level now surpassed.
Delivery volumes have also shown significant improvement, with a 1-month delivery change of 94.85% and a 1-day delivery change of 71.91% compared to the 5-day average, indicating increased investor conviction and liquidity.
Quality Assessment and Capital Structure
Venus Remedies is classified as an average quality company based on long-term financial performance metrics. It boasts excellent capital structure with minimal debt, reflected in an average debt to EBITDA ratio of 0.54 and a net cash position. Interest coverage remains very strong at 50.94 times, and there is no promoter share pledging. The company’s 5-year EBIT growth rate of 45.72% and sales growth of 7.02% demonstrate solid operational expansion.
While the average return on equity (ROE) and return on capital employed (ROCE) over the long term are moderate at 8.61% and 9.53% respectively, recent half-year figures show marked improvement, with ROCE reaching 19.85%. The company’s tax ratio stands at 23.37%, and it has maintained a zero dividend payout ratio in recent periods.
Summary of Recent Financial Trends
The latest quarterly results highlight a positive short-term financial trend. Key metrics such as PAT, net sales, and operating profit have all reached record highs. The company’s earnings per share (EPS) for the quarter stood at Rs. 35.53, the highest recorded to date. Operating profit to net sales ratio also improved to 24.45%, reflecting enhanced profitability.
Cash and cash equivalents were noted as the lowest at Rs. 29.61 crores in the half-year period, a factor to monitor in the context of working capital management.
Conclusion
Venus Remedies Ltd’s achievement of a new all-time high price of Rs. 2,037.9 on 29 June 2026 marks a significant milestone in its market journey. Supported by strong financial results, consistent growth, and a solid technical outlook, the company has demonstrated resilience and market leadership within the Pharmaceuticals & Biotechnology sector. Its sustained outperformance relative to the Sensex and sector benchmarks over multiple time frames highlights the strength of its business model and operational execution.
With a net-debt free balance sheet, expanding institutional interest, and a history of positive quarterly results, Venus Remedies continues to solidify its position as a noteworthy micro-cap stock in the Indian equity market.
